Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: Reversing and preventing as different electrophysiological mechanisms

Panminerva Medica

Volumn 41, Issue , 1999, Pages 295-306

  Masotti, C S ^a,b   Pierangeli, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; SODIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANTI-ARRHYTHMIA AGENTS; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; SODIUM CHANNEL BLOCKERS; TACHYCARDIA, VENTRICULAR;

EID: 0033252957     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. De Bakker JM, Coronel R, Tasseron S. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. JACC, 1990;15:1594-607.
2. Bigger JT, Fleiss JL, Kleiger R. The relationship among ventricular arrhythmias, left ventricular dysfunction and mortality in the two years after myocardial infarction. Circulation, 1984 ;69:250-8.
3. Califf RM, Burks JM, Behar VS. Relationships among ventricular arrhythmias, coronary artery disease, and angiographic and electrophysiologic indicators of myocardial fibrosis. Circulation, 1978; 57:725-32.
4. Kay GN, Epstein AE, Plumb VJ. Resetting of ventricular tachycardia by single extrastimuli. Circulation, 1990;81:1507-19.
5. Koonlawee N, Stevenson WG, Weiss JN. Frequency-dependent effect of quinidine on the ventricular action potential and QRS duration in humans. Circulation, 1990;81:790-6.
6. Anderson KP, Walker R, Lux RL. Conduction velocity depression and drug-induced ventricular tachyarrhythmias. Effects of lidocaine in the intact canine heart. Circulation, 1990;81:1024-3.
7. Lie KI, Wellens HJ, Van Capelle FJ. Lidocaine in the prevention of primary ventricular fibrillation. A double-blind randomized study of 212 consecutive patients. N Engl J Med, 1974;291:1324-6.
8. Dunn HM, McComb JM, Kinney CD. Prophylactic lidocaine in the early phase of suspected myocardial infarction. Am Heart J, 1985;110:353-62.
9. Wise DG, Kellen J, Rademaker AW. Prophylactic vs selective lidocaine for early ventricular arrhythmias of myocardial infarction. JACC, 1988;12:507-13.
10. McMahon S, Collins R, Peto R. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA, 1988;260:1910-6.
11. Hine LK, Laird N, Hewitt P. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med, 1989;149:2694-8.
12. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trial in heart disease. I. Treatments following myocardial infarction. JAMA, 1988;230:2088-93.
13. Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction: implications for the prophylactic use of lidocaine. Circulation, 1992;86:764-73.
14. The Cardiac Arrhythmia Suppression Trial Investigators. Increased mortality due to flecainide and encainide in a randomized trial of arrhythmia suppression aner myocardial infarction. N Engl J Med, 1989;321:406-12.
15. Brugada J, Boersma L, Kirchhof C. Double-wave reentry as a mechanism of acceleration of ventricular tachycardia. Circulation 1990;81:1633-43.
16. Fromer M, Schlapfer J, Fischer A, Kappenberger L. Experience with a new implantable pacer-, cardioverter-, defibrillator for the therapy of recurrent sustained ventricular tachyarrhythmias: A step toward a universal tachyarrhythmia control device. PACE 1991;14:1288-98.
17. Dennis AR, Richards DA, Cody DV. Prognostic symptoms of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiogram of survivor of acute myocardial infarction. Circulation, 1986;74:731-45.
18. Steinberg JS, Bigger JT. Importance of the end-point of noise reduction in analysis of the signal-averaged electrocardiogram. Am J Cardiol, 1989;63:556-60.
19. Vatterott PJ, Bailey KR, Hammil SC. Improving of predicting ability of the signal-averaged electrocardiogram with a linear logistic model incorporating clinical variables. Circulation, 1990;81:797-804.
20. Simonson JS, Gang ES, Diamond GA. Selection of patients for programmed ventricular stimulation: a clinical decision making model based on multivariate analysis of clinical variables. JACC, 1992; 20:317-27.
21. Malik M, Kulakowski P, Poloniecki J. Frequency vs time domain analysis of signal-averaged electrocardiograms. I. Reproducibility of the results. JACC 1992;20:127-34.
22. Kulakowski P, Malik M, Poloniecki J. Frequency vs time domain of signal-averaged electrocardiograms. II. Identification of patients with ventricular tachycardia after myocardial infarction. JACC, 1992;20:135-43.
23. Odemuyiwa O, Malik M, Poloniecki J. Frequency vs time domain analysis of signal averaged electrocardiograms. III. Stratification of postinfarction patients for arrhythmic events. JACC, 1992; 20:144-50.
24. Lander P, Berbari EJ. Principles and signal processing techniques of the high resolution ECG. Prog Cardiovasc Dis 1992;35:169-88.
25. Lander P, Berbari EJ, Rajagopalam CY. Critical analysis of the signal-averaged electrocardiogram: improved identification of late potentials. Circulation, 1993;87:105-17.
26. Breithardt G, Cain ME, El-Sherif M. Standards for analysis of ventricular late potentials using high resolution or signal-averaged electrocardiography: a statement by a task force committee of the European Society of Cardiology, the American Heart Association and the American College of Cardiology. JACC, 1991;17:999-1006.
27. Gardner MJ, Montague TJ, Armstrong CS. Vulnerability to ventricular arrhythmia: Assessment by mapping of body surface potentials. Circulation, 1986;73:684-92.
28. Horacek BM, Montague TJ, Gardner MJ, Smith ER. Arrhythmogenic conditions. In: Mirvis DM, editor. Body surface electrocardiographic mapping. Boston: Martinus Nijhoff, 1987:167-89.
29. De Ambroggi L, Bertoni T, Locati E. Mapping of body surface potentials in patients with idiopathic long QT syndrome. Circulation, 1986;74:1334-45.
30. Tsunakawa H, Nishiyama G, Kusahana Y. Identification of susceptibility to ventricular tachycardia after myocardial infarction by nondipolarity of QRST area maps. JACC, 1989;14:1530-6.
31. Mitchell LB, Hubley-Kozey CL, Smith ER. Electrocardiographic body surface mapping in patients with ventricular tachycardia: assessment of utility in the identification of effective pharmacological therapy. Circulation, 1992;86:383-93.
32. Josephson ME, Horowitz LN, Spielman SR. Role of catheter mapping in the preoperative evaluation of ventricular tachycardia. Am J Cardiol 1982;49:207-20.
33. Masotti CS, Bonfranceschi P, Rusticali F, Pierangeli A. Malignant ventricular arrhythmias: clinical guidelines for diagnosis and treatment. Panminerva Med 1991;33:191-6.
34. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Circ Res 1986;58:356-71.
35. Haws CW, Lux RL. Correlation between in vivo transmembrane action potential durations and activation-recovery intervals from electrograms: effect of interventions which alter repolarization time. Circulation, 1990;81:281-8.
36. Starmer CF, Anselmo AL, Nesterenko VV, Grant AO. Proarrhythmic response to sodiun channel blockade: theoretical model and numerical experiments. Circulation, 1991;84:1364-77.
37. Nattel S. Frequency-dependent effects of amytriptiline on ventricular conduction and cardiac rhythm. Circulation, 1985;72:898-906.
38. Kidwell GA, Greenspon AJ, Greenberg RM, Volosin KJ. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans. Circulation, 1993;87:118-25.
39. Hondeghem L, Katzung BG. Time and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochem Biophys Acta 1977;472:373-98.
40. Hondeghem L, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel blocking drugs. Ann Rev Pharmacol Toxicol 1984;24:387-423.
41. Starmer CF, Grant AO, Strauss HC. Mechanism of the use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J 1984;46:15-27.
42. Grant AO, Starmer CF, Strauss HC. Antiarrhythmic drug action: blockade of the inward sodium current. Circ Res 1984;55:427-39.
43. Wasserstrom JA, Salata JJ. Basis for tetrodotoxin and lidocaine effects on action potential in dog ventricular myocytes. Am J Physiol 1988;254:H1157-H1166.
44. Rosen MR, Hoffman BF, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine. Am Heart J, 1975;89:526-36.
45. Roden DM, Thompson KA, Hoffman BF. Clinical features and basic mechanisms of quinidine-induced arrhythmias. JACC, 1986;8:73A-78A.
46. Carson DL, Cardinal R, Savard P. Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. J Cardiovasc Pharmacol 1986;8:126-36.
47. Patterson E, Gibson JK, Lucchesi BR. Electrophysiologic action of lidocaine in a canine model of chronic myocardial ischemic damage. Arrhythmogenic action of lidocaine 1982;4:925-34.
48. Hunt GB, Ross DL. Promotion of ventricular tachycardia induction by procainamide in dogs with inducible ventricular fibrillation late after myocardial infarction. PACE 1990;13:882-9.
49. Buxton AE, Josephson ME, Marchlinski FE, Miller JM. Polymorphic ventricular tachycardia induced by programmed stimulation: response to procainamide. JACC, 1993;21:90-8.
50. Gettes LS. Effect of ischemia on cardiac electrophysiology. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The Heart and Cardiovascular system. New York: Raven Press 1986:1317-41.
51. Mason JW. Amiodarone. N Engl J Med 1987;316:455-65.
52. Jorens PG, Van Den Heuvel PA, Ranquin REF. Amiodarone-induced torsade de points: report of three cases and review of literature. Acta Cardiol 1989;5:411.
53. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and the QT interval. Circulation, 1988;74:340-9.
54. Mattioni TA, Heutlin TA, Sarmiento JJ. Amiodarone in patients with previous drug-mediated torsade de points: long-term safety and efficacy. Ann Intern Med 1989;111:574-80.
55. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmic risk in patients with long QT intevals. Br Heart J 1990;63:342-4.
56. Higham PD, Fumiss SS, Campbell RWF. QT dispersion in ischemia and infarction: a marker of primary ventricular fibrillation? Eur Heart J, 1991;12:87(abstract).
57. Day CP, McComb JM, Mattwes J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991;12:423-7.
58. Hii JTY, Wyse G, Gillis AM. Precordial QT interval dispersion as a marker of torsade de points: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation, 1992;86:1376-82.
59. Friehling TD, Lipshutz H, Marinchak RA. Effectiveness of propanolol added to type I antiarrhythmic agents for sustained ventricular tachycardia secondary to coronary artery disease. Am J Cardiol 1990;65:1328-33.
60. Myerburg RJ, Kessler KM, Cox MM. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrocloride by propanolol. Circulation, 1989;80:1571-9.
61. Kent KM, Smith ER, Redwood DR, Epstein SE. Electrical stability of acutely ischemic myocardium: influences of heart rate and vagal stimulation. Circulation, 1973;67:291-8.
62. Gottlieb, Josephson. In: Cardiac arrhythmias, where to go from here. Brugada P, Wellens HJJ. Futura, 1987:421.
63. Mostow ND, Rakita L, Vrobel TR. Amiodarone: intravenous loading for rapid suppression of complex ventricular arrhythmias. JACC, 1984;4:97-104.
64. Mostow ND, Rakita L, Vrobel TR. Amiodarone: correlation of serum concentration with suppression of complex ventricular ectopic activity. Am J Cardiol, 1984;54:58-74.
65. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol 1989;64:1138-43.
66. Giardina EV, Schneider M, Barr ML. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing myocardial transplantation. JACC, 1990;16:943-7.